News & Events

All the latest news and events from PhoreMost

PhoreMost closes £33M ($46M) Series B financing
23rd March 2021

PhoreMost closes £33M ($46M) Series B financing

Funding to support progression of PLK1 program, for treatment of brain cancer, into the clinic within 18 months Company is advancing its pipeline of novel therapies for oncology and diseases of ageing, and developing novel therapeutic modalities in the targeted protein degradation space Oversubscribed investment round led by BGF, with XtalPi, Astellas Venture Management, Trend Investment Group, …

PhoreMost and Sentinel Oncology expand collaboration to jointly accelerate novel glioma therapeutic through preclinical development
4th November 2019

PhoreMost and Sentinel Oncology expand collaboration to jointly accelerate novel glioma therapeutic through preclinical development

PhoreMost named ‘Biotech Company of the Year’ at Cambridge Independent Science and Technology Awards 2019
31st October 2019

PhoreMost named ‘Biotech Company of the Year’ at Cambridge Independent Science and Technology Awards 2019

PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director
15th July 2019

PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director

PhoreMost and inStem enter structural biology alliance
8th July 2019

PhoreMost and inStem enter structural biology alliance

PhoreMost and C4X Discovery announce neurodegeneration focused drug discovery collaboration
25th June 2019

PhoreMost and C4X Discovery announce neurodegeneration focused drug discovery collaboration

PhoreMost and Ligand Subsidiary Vernalis Limited Announce Drug Discovery Collaboration for Novel Oncology Target
12th June 2019

PhoreMost and Ligand Subsidiary Vernalis Limited Announce Drug Discovery Collaboration for Novel Oncology Target

No events currently available